Analysts Set AstraZeneca PLC (LON:AZN) Target Price at £104.12

Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is £104.12 ($129.39).

A number of research analysts recently weighed in on AZN shares. JPMorgan Chase & Co. reiterated an "overweight" rating and issued a £140 ($173.98) target price on shares of AstraZeneca in a report on Friday, November 22nd. Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a research report on Thursday, November 7th.

AstraZeneca Trading Down 0.3 %

Shares of LON AZN traded down GBX 36 ($0.45) during midday trading on Friday, reaching £105.94 ($131.65). 2,876,430 shares of the stock were exchanged, compared to its average volume of 2,731,025. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The company has a market capitalization of £164.21 billion, a P/E ratio of 3,363.17, a P/E/G ratio of 0.86 and a beta of 0.17. The stock has a 50 day moving average price of £105.60 and a 200-day moving average price of £117.11. AstraZeneca has a 52-week low of GBX 9,461 ($117.57) and a 52-week high of £133.88 ($166.37).

Insider Activity

In related news, insider Pascal Soriot bought 20,000 shares of the company's stock in a transaction on Thursday, November 14th. The shares were purchased at an average cost of £102.03 ($126.79) per share, with a total value of £2,040,600 ($2,535,851.87). Also, insider Tony Mok bought 1,500 shares of AstraZeneca stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of £126.80 ($157.57) per share, with a total value of £190,200 ($236,361.38). Company insiders own 0.04% of the company's stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.